Contribution of radiation therapy of head and neck paragangliomas: About 6 cases presentation

Yıl 2019, Cilt: 3 Sayı: 2, 197 - 201, 25.02.2019

Sanae Ghammad , Allouche Fadwa Terrab Fatima Zahra Chebihi Hassani Ghita Alami Zenab Bouhafa Thouria Hassouni Khalid

https://doi.org/10.28982/josam.475604

Öz

The neck’s paraganglions are bilateral nodular structures, with the same embryological origin which is the cephalic neural crest. They have a branchiomeric distribution. They have an important secreting function during the embryonic life, and then regress when the adrenal medulla starts functioning. Then only carotid and aortic paraganglions have chemoreceptor, baroreceptor and endocrine proved functions. The paragangliomas are tumors developed at the expense of paraganglions by proliferations of the chief cells (of type I) most of the time. Generally these tumors exhibit a slow growth rate, most often presenting asymptomatically as a space occupying mass lesion witnessed clinically or radiographically. The secreting tumors are very rare (5%). The benignity is the rule but the localization near noble structures makes it a highly risky tumor. This disease is often monofocal but it may also be part of a multifocal disease (6%). Advances in imaging have facilitated the diagnosis and the assessment of this disease. Diagnosis is generally made through a combination of clinical findings and radiographic studies. Surgery is the treatment of choice through total subadventitial resection, and rebuilding of the carotid axis when necessary. Surgery may lead to significant morbidity, resulting from major cranial nerve injury and especially at a late stage in the evolution of the disease. The preoperative embolization can facilitate ablation and reduce morbidity. Precisely, external radiotherapy can de indicated for recurrences, tumoral operating residues, and counter indications.

Anahtar Kelimeler

Paraganglioma, Radiotherapy, Head and neck, Pheochromocytoma

Baş ve boyun paragangliomalarında radyasyon tedavisinin katkısı: 6 vaka sunumu

Öz

Boynun paraganglionları, sefalik sinir kreti olan aynı embriyolojik kökene sahip iki taraflı nodüler yapılardır. Branşmerik dağılımları var. Embriyonik yaşam boyunca önemli bir salgılama fonksiyonuna sahiptirler ve adrenal medulla çalışmaya başladığında gerilerler. O zaman sadece karotis ve aort paraganglionları kemorekeptör, barorekeptör ve endokrin kanıtlanmış fonksiyonlara sahiptir. Paragangliomalar, çoğu zaman baş hücrelerin çoğalmasıyla (tip I) paraganglionlar pahasına geliştirilen tümörlerdir. Genellikle bu tümörler, klinik veya radyografik olarak tanık olan bir yer kaplayan kitle lezyonu olarak asemptomatik olarak ortaya çıkan yavaş bir büyüme hızı gösterir. Salgılanan tümörler çok nadirdir (% 5). Benignity kural ama asil yapılara yakın lokalizasyon onu oldukça riskli bir tümör yapar. Bu hastalık genellikle monofokaldir, fakat aynı zamanda multifokal bir hastalığın parçası olabilir (% 6). Görüntüleme alanındaki ilerlemeler, bu hastalığın teşhis ve değerlendirmesini kolaylaştırmıştır. Tanı genellikle klinik bulgular ve radyografik incelemelerin bir kombinasyonu ile yapılır. Cerrahi, total subadventitial rezeksiyon ve gerektiğinde karotis ekseninin yeniden inşası ile tercih edilen tedavi yöntemidir. Cerrahi, önemli kranial sinir yaralanmasından kaynaklanan ve özellikle hastalığın evriminde geç bir aşamada ciddi morbiditeye yol açabilir. Preoperatif embolizasyon ablasyonu kolaylaştırabilir ve morbiditeyi azaltabilir. Kesin olarak, dış radyoterapi nüks, tümörlü çalışma artıkları ve karşı endikasyonlar için gösterilebilir.

Anahtar Kelimeler

Paraganglioma, Radyoterapi, Baş ve boyun, Feokromositoma

Kaynakça

• 1. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39;617–22.
• 2. Van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ. Genomic imprinting in hereditary glomus tumors: evidence for new genetic theory. Lancet. 1989;2:1291-4.
• 3. Opocher G, Schiavi F. Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2010;24:943-56.
• 4. van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH, van de Kamp JJ. Genomic imprinting in hereditary glomus tumors: evidence for new genetic theory. Lancet. 1989;ii:1291–4.
• 5. Heutink P, van der Mey AG, Sandkuijl LA, et al. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet. 1992;1:7–10.
• 6. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000;26:268–70.
• 7. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001;69:49–54.
• 8. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, Rutter J. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009;28:1139–42.
• 9. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–51.
• 10. Lips CJM, Lentjes EGWM, Höppener JWM, van der Luijt RB, Moll FL. Familial paragangliomas: Hereditary Cancer in Clinical Practice. 2006;4:169.
• 11. Hayes WS, Davidson AJ, Grimley PM, Hartman DS. Extraadrenal retroperitoneal paraganglioma: clinical, pathologic and CT finding AJR Am. J Roentgenol. 1990;155:1247- 50.
• 12. Bessell-Browne R, O_Malley ME. CT of pheochromocytoma and paraganglioma; risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188:970-4.
• 13. Baeza JC, Jagannathanb JB, Krajewskib K, Kevin O. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012;12:153-62.
• 14. Miliaras GC, Kyristis AP, Polyzoidis KS. Cauda equina 383 paraganglioma: a review. Journal of Neuro-oncology. 2003;65:177–90.
• 15. World Health Organization. Pathology and Genetics: Tumors of Endocrine Organs. Lyon, France: IARC;2004.
• 16. Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gläsker S, et al. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo). 2012;67 Suppl 1:19-28.
• 17. Gilbo P, Morris CG, Amdur RJ, Werning JW, Dziegielewski PT, Kirwan J, Mendenhall WM. Radiotherapy for benign head and neck paragangliomas: a 45-year experience. Cancer. 2014 Dec 1;120(23):3738-43.
• 18. Foote RL, Pollock BE, Gorman DA, et al. Glomus jugulare tumor: tumor control and complications after stereotactic radiosurgery. Head Neck. 2002;24:332-8.
• 19. Suarez C, Rodrigo JP, Bodeker CC, et al. Jugular and vagal paragangliomas: systematic study of management with surgery and radiotherapy. Head Neck. 2013;35:1195-04.
• 20. Jacob JT, Link MJ, Foote RL, Pollock BE. Stereotactic radiosurgery for glomus tumors. New York, NY: Thieme Medical Publishers, Inc; 2009